{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:35:37Z","timestamp":1793745337202,"version":"4.6.1"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007949","name":"Swedish Rheumatism Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014688","name":"Region Uppsala","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014688","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009230","name":"Landstinget i Uppsala l\u00e4n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007366","name":"Agnes and Mac Rudberg foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.clim.2025.110476","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T15:14:27Z","timestamp":1742397267000},"page":"110476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Diffuse large B cell lymphoma in rheumatoid arthritis patients is associated with elevated B-cell driving factors including CXCL13"],"prefix":"10.1016","volume":"275","author":[{"given":"Nora","family":"Euler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Hellbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik af","family":"Klint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunilla","family":"Enblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivianne","family":"Malmstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Baecklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Gr\u00f6nwall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2025.110476_bb0005","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(09)60008-8","article-title":"Rheumatoid arthritis","volume":"373","author":"Klareskog","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2025.110476_bb0010","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41584-024-01124-6","article-title":"The peculiar features, diversity and impact of citrulline-reactive autoantibodies","volume":"20","author":"Raposo","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.clim.2025.110476_bb0015","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/jnci\/85.4.307","article-title":"Incidence of Cancer among patients with rheumatoid arthritis","volume":"85","author":"Gridley","year":"1993","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.clim.2025.110476_bb0020","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1002\/art.22277","article-title":"Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2025.110476_bb0025","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2025.110476_bb0030","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1093\/rheumatology\/keaa330","article-title":"For the ARTIS study group, lymphoma risks in patients with rheumatoid arthritis treated with biological drugs\u2014a Swedish cohort study of risks by time, drug and lymphoma subtype","volume":"60","author":"Hellgren","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.clim.2025.110476_bb0035","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz5327","article-title":"Persistently activated, proliferative memory autoreactive B cells promote inflammation in rheumatoid arthritis","volume":"12","author":"Kristyanto","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.clim.2025.110476_bb0040","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1749-6632.2003.tb06055.x","article-title":"Aberrant activation of B cells in patients with rheumatoid arthritis","volume":"987","author":"Lindenau","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.clim.2025.110476_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128269","article-title":"Expansion of activated peripheral blood memory B cells in rheumatoid arthritis, Impact of B cell depletion therapy, and biomarkers of response","volume":"10","author":"Adlowitz","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2025.110476_bb0050","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.clim.2025.110476_bb0055","series-title":"The Biology of Human Lymphoid Malignancies Revealed by Gene Expression Profiling, in: Adv. Immunol","first-page":"163","author":"Staudt","year":"2005"},{"key":"10.1016\/j.clim.2025.110476_bb0060","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/imr.12755","article-title":"Germinal center-derived lymphomas: the darkest side of humoral immunity","volume":"288","author":"Mlynarczyk","year":"2019","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.clim.2025.110476_bb0065","first-page":"1","article-title":"Cytokines as biomarkers in rheumatoid arthritis","volume":"2014","author":"Burska","year":"2014","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.clim.2025.110476_bb0070","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/art.30273","article-title":"Identification of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint","volume":"63","author":"Meeuwisse","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2025.110476_bb0075","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.lfs.2019.04.053","article-title":"CXCL13\/CXCR5 signaling axis in cancer","volume":"227","author":"Hussain","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.clim.2025.110476_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2023.156289","article-title":"Cytokine profiles in patients with newly diagnosed diffuse large B-cell lymphoma: IL-6 and IL-10 levels are associated with adverse clinical features and poor outcomes","volume":"169","author":"Bao","year":"2023","journal-title":"Cytokine"},{"key":"10.1016\/j.clim.2025.110476_bb0085","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1038\/s41598-022-06877-2","article-title":"Comprehensive analysis of the expression and significance of CXCLs in human diffuse large B-cell lymphoma","volume":"12","author":"Zhou","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.clim.2025.110476_bb0090","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1126\/science.1077002","article-title":"A critical role for IL-21 in regulating immunoglobulin production","volume":"298","author":"Ozaki","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.clim.2025.110476_bb0095","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cytogfr.2013.04.003","article-title":"The BAFF\/APRIL system: emerging functions beyond B cell biology and autoimmunity","volume":"24","author":"Vincent","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.clim.2025.110476_bb0100","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1182\/blood-2011-01-332106","article-title":"CXCL13\/CXCR5 signaling enhances BCR-triggered B-cell activation by shaping cell dynamics","volume":"118","author":"S\u00e1ez De Guinoa","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clim.2025.110476_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.627986","article-title":"A comprehensive evaluation of the relationship between different IgG and IgA anti-modified protein autoantibodies in rheumatoid arthritis","volume":"12","author":"Gr\u00f6nwall","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2025.110476_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105320","article-title":"Autoreactive B cells against malondialdehyde-induced protein cross-links are present in the joint, lung, and bone marrow of rheumatoid arthritis patients","volume":"299","author":"Sahlstr\u00f6m","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.clim.2025.110476_bb0115","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/art.38969","article-title":"Malondialdehyde-acetaldehyde adducts and anti\u2013malondialdehyde-acetaldehyde antibodies in rheumatoid arthritis","volume":"67","author":"Thiele","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.clim.2025.110476_bb0120","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.kjms.2013.01.013","article-title":"Judging disease activity in rheumatoid arthritis by serum free kappa and lambda light chain levels","volume":"29","author":"Ye","year":"2013","journal-title":"Kaohsiung J. Med. Sci."},{"key":"10.1016\/j.clim.2025.110476_bb0125","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Weltgesundheits organisation","year":"2017"},{"key":"10.1016\/j.clim.2025.110476_bb0130","first-page":"1860","article-title":"Report of the committee on Hodgkin\u2019s disease staging classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res."},{"key":"10.1016\/j.clim.2025.110476_bb0135","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"2010","key":"10.1016\/j.clim.2025.110476_bb0140","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European league against rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2025.110476_bb0145","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/0284186X.2017.1337926","article-title":"U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden","volume":"57","author":"Glimelius","year":"2018","journal-title":"Acta Oncol."},{"key":"10.1016\/j.clim.2025.110476_bb0150","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/art.40852","article-title":"Complex relationships of smoking, HLA\u2013DRB1 genes, and serologic profiles in patients with early rheumatoid arthritis: update from a swedish population-based case\u2013control study","volume":"71","author":"Hedstr\u00f6m","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.clim.2025.110476_bb0155","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/annrheumdis-2016-209297","article-title":"Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs","volume":"76","author":"Figueiredo","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2025.110476_bb0160","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13075-018-1530-2","article-title":"Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus is associated with disease activity and nephritis","volume":"20","author":"Hardt","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.clim.2025.110476_bb0165","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.clim.2017.09.013","article-title":"Depressed serum IgM levels in SLE are restricted to defined subgroups","volume":"183","author":"Gr\u00f6nwall","year":"2017","journal-title":"Clin. Immunol. Orlando Fla"},{"key":"10.1016\/j.clim.2025.110476_bb0170","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaut.2017.06.004","article-title":"Autoreactivity to malondialdehyde-modifications in rheumatoid arthritis is linked to disease activity and synovial pathogenesis","volume":"84","author":"Gr\u00f6nwall","year":"2017","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.clim.2025.110476_bb0175","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.clim.2025.110476_bb0180","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/clinchem\/48.9.1437","article-title":"Serum reference intervals and diagnostic ranges for free \u03ba and free \u03bb immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains","volume":"48","author":"Katzmann","year":"2002","journal-title":"Clin. Chem."},{"key":"10.1016\/j.clim.2025.110476_bb0185","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clim.2025.110476_bb0190","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41416-021-01525-4","article-title":"Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year real world data of practice patterns and outcomes in England","volume":"126","author":"Hounsome","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.clim.2025.110476_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106700","article-title":"Factors affecting survival in elderly patients with diffuse large B-cell lymphoma","volume":"110","author":"Ulu","year":"2021","journal-title":"Leuk. Res."},{"key":"10.1016\/j.clim.2025.110476_bb0200","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1186\/s13075-014-0434-z","article-title":"CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic `window of opportunity","volume":"16","author":"Greisen","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.clim.2025.110476_bb0205","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1093\/rheumatology\/keu163","article-title":"High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease","volume":"53","author":"Bugatti","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.clim.2025.110476_bb0210","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1182\/blood-2011-01-332106","article-title":"CXCL13\/CXCR5 signaling enhances BCR-triggered B-cell activation by shaping cell dynamics","volume":"118","author":"S\u00e1ez De Guinoa","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clim.2025.110476_bb0215","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00296-020-04524-5","article-title":"Serum CXCL13 levels are associated with lymphoma risk and lymphoma occurrence in primary Sj\u00f6gren\u2019s syndrome","volume":"40","author":"UK primary Sj\u00f6gren\u2019\u2019s syndrome registry","year":"2020","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.clim.2025.110476_bb0220","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nri802","article-title":"Development of anti-TNF therapy for rheumatoid arthritis","volume":"2","author":"Feldmann","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.clim.2025.110476_bb0225","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1586\/1744666X.2014.894886","article-title":"The CXCL8\/IL-8 chemokine family and its receptors in inflammatory diseases","volume":"10","author":"Russo","year":"2014","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.clim.2025.110476_bb0230","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/JLB.3MA1217-502R","article-title":"The chemokine fragment CXCL9(74\u2013103) diminishes neutrophil recruitment and joint inflammation in antigen-induced arthritis","volume":"104","author":"Boff","year":"2018","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.clim.2025.110476_bb0235","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.leukres.2017.05.014","article-title":"High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma","volume":"59","author":"Dlouhy","year":"2017","journal-title":"Leuk. Res."},{"key":"10.1016\/j.clim.2025.110476_bb0240","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1158\/0008-5472.CAN-16-0786","article-title":"CXCL-8\/IL8 produced by diffuse large B-cell lymphomas recruits neutrophils expressing a proliferation-inducing ligand APRIL","volume":"77","author":"Manfroi","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.clim.2025.110476_bb0245","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.biopha.2018.07.171","article-title":"CXCL9 promotes the progression of diffuse large B-cell lymphoma through up-regulating \u03b2-catenin","volume":"107","author":"Ruiduo","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.clim.2025.110476_bb0250","doi-asserted-by":"crossref","first-page":"R167","DOI":"10.1186\/ar2076","article-title":"Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis","volume":"8","author":"Vallerskog","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.clim.2025.110476_bb0255","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/art.21650","article-title":"Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse","volume":"54","author":"Cambridge","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2025.110476_bb0260","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1038\/jid.2009.27","article-title":"Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris","volume":"129","author":"Nagel","year":"2009","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.clim.2025.110476_bb0265","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/rheumatology\/keq337","article-title":"CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis","volume":"50","author":"Rosengren","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.clim.2025.110476_bb0270","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1136\/annrheumdis-2011-200975","article-title":"Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort","volume":"71","author":"Gottenberg","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2025.110476_bb0275","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3892\/ol.2014.2062","article-title":"Effect of interleukin 21 and its receptor on CD8+ T cells in the pathogenesis of diffuse large B-cell lymphoma","volume":"8","author":"Cha","year":"2014","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.clim.2025.110476_bb0280","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/bjh.13659","article-title":"CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma","volume":"171","author":"Takahashi","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.clim.2025.110476_bb0285","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/03009742.2017.1376108","article-title":"Anti-cyclic citrullinated peptide antibodies, other common autoantibodies, and smoking as risk factors for lymphoma in patients with rheumatoid arthritis","volume":"47","author":"Baecklund","year":"2018","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.clim.2025.110476_bb0290","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/ard.2006.052159","article-title":"Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren\u2019s syndrome","volume":"66","author":"Gottenberg","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2025.110476_bb0295","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1158\/1078-0432.CCR-13-3203","article-title":"Serum Interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins","volume":"20","author":"Sanmamed","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2025.110476_bb0300","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1182\/blood-2011-10-388538","article-title":"Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation","volume":"119","author":"Gupta","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clim.2025.110476_bb0305","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/hon.2374","article-title":"Serum level of CXCL10 is associated with inflammatory prognostic biomarkers in patients with diffuse large B -cell lymphoma","volume":"35","author":"Hong","year":"2017","journal-title":"Hematol. Oncol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661625000518?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661625000518?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:38:15Z","timestamp":1762547895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661625000518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":61,"alternative-id":["S1521661625000518"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2025.110476","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diffuse large B cell lymphoma in rheumatoid arthritis patients is associated with elevated B-cell driving factors including CXCL13","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2025.110476","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110476"}}